Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Безопасность комбинации карбоплатина и пегилированного липосомального доксорубицина в первой линии терапии больных раком яичников: предварительные результаты рандомизированного исследования MITO-2
Безопасность комбинации карбоплатина и пегилированного липосомального доксорубицина в первой линии терапии больных раком яичников: предварительные результаты рандомизированного исследования MITO-2
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Mc Guire WP, Hoskins WJ et al. Cyclophosphamide and cisplatin compared with pladitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med; 334: 6.
2. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cispatin-paditaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699–708.
3. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paditaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–200.
4. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of cisplatin and paditaxel versus carboplatin and paclitaxel in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084–92.
5. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J NatlCancer Inst 2003; 95: 1320–29.
6. Bristow RE, Tomacruz RS, Armstrong DK et al. Survivaleffect of maximal cytoreductive surgery for advance ovarian cancer in the platinum era: a metanalysis. J Clin Oncol 2002; 20: 1248–59.
7. Ozols RF, Willson JK, Weltz MD et al. Inhibition of human ovarian cancer colony formation by Adriamicin and its metabolites. Cancer Res 1980; 40: 109–12.
8. Ovarian Cancer Meta-Analysis Project: Cydophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma. J Clin Oncol 1991; 9: 1668–74.
9. A'Hern R, Gore ME. The impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726–32.
10. Vaage J, Donovan D, Mayhew E et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993; 72: 3671–75.
11. Sakakibara T, Chen FA, Kida H et al. Doxorubicin encapsulated in strerically stabolized liposomes is superior to free drug or drug-containing conventional liposomes at supperssing growth and metastases of human lung tumors xenografts. Cancer Res 1996; 56: 3743–6.
12. Vaage J, Donovan D, Uster P, Working P. Tumor uptade of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 1997; 75: 482–6.
13. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer. Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–93.
14. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum-paclitaxel refractory epithelial ovarian cancer. J Clin Oncol 200; 18: 3093–100.
15. Safra T, Groshen S, Jeffers S et al. Treatment of patients with ovarian carcinoma with pehylated liposomal doxorubicin. Analysis of toxicities and predictors of outcome. Canser 2001; 91: 90–100.
16. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2000; 19: 3312–22.
17. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 2004; 95: 1–8.
18. Ferrero JM, Weber B, Lepille D et al. Caelyx and Carboplatin in patients with advanced ovarian cancer in late relapse (>6 months): late results of a GINECO phase II trial [abstract]. proc Am Soc Clin Oncol 2004; 23: 53 (Abstr 5022).
19. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospect of evaluation of a simle formula based on renal function. J Clin Oncol 1989; 7: 1748–56.
20. National Cancer Institute – Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0 April 30, 1999 [http://ctep.info.nih.gov].
21. du Bois A, Burges A, Meier W et al. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Ondologie Studiengruppe ovarialkarzinom (AGO-OVAR). Ann Oncol 2006; 17: 93–6.
2. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cispatin-paditaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699–708.
3. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paditaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–200.
4. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of cisplatin and paditaxel versus carboplatin and paclitaxel in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084–92.
5. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J NatlCancer Inst 2003; 95: 1320–29.
6. Bristow RE, Tomacruz RS, Armstrong DK et al. Survivaleffect of maximal cytoreductive surgery for advance ovarian cancer in the platinum era: a metanalysis. J Clin Oncol 2002; 20: 1248–59.
7. Ozols RF, Willson JK, Weltz MD et al. Inhibition of human ovarian cancer colony formation by Adriamicin and its metabolites. Cancer Res 1980; 40: 109–12.
8. Ovarian Cancer Meta-Analysis Project: Cydophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma. J Clin Oncol 1991; 9: 1668–74.
9. A'Hern R, Gore ME. The impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726–32.
10. Vaage J, Donovan D, Mayhew E et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993; 72: 3671–75.
11. Sakakibara T, Chen FA, Kida H et al. Doxorubicin encapsulated in strerically stabolized liposomes is superior to free drug or drug-containing conventional liposomes at supperssing growth and metastases of human lung tumors xenografts. Cancer Res 1996; 56: 3743–6.
12. Vaage J, Donovan D, Uster P, Working P. Tumor uptade of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 1997; 75: 482–6.
13. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer. Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–93.
14. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum-paclitaxel refractory epithelial ovarian cancer. J Clin Oncol 200; 18: 3093–100.
15. Safra T, Groshen S, Jeffers S et al. Treatment of patients with ovarian carcinoma with pehylated liposomal doxorubicin. Analysis of toxicities and predictors of outcome. Canser 2001; 91: 90–100.
16. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2000; 19: 3312–22.
17. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 2004; 95: 1–8.
18. Ferrero JM, Weber B, Lepille D et al. Caelyx and Carboplatin in patients with advanced ovarian cancer in late relapse (>6 months): late results of a GINECO phase II trial [abstract]. proc Am Soc Clin Oncol 2004; 23: 53 (Abstr 5022).
19. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospect of evaluation of a simle formula based on renal function. J Clin Oncol 1989; 7: 1748–56.
20. National Cancer Institute – Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0 April 30, 1999 [http://ctep.info.nih.gov].
21. du Bois A, Burges A, Meier W et al. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Ondologie Studiengruppe ovarialkarzinom (AGO-OVAR). Ann Oncol 2006; 17: 93–6.
Авторы
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.